August 16, 2024
Certara Launches Phoenix™ Version 8.5 Drug Development Software
RADNOR, Pa., Aug. 15, 2024 (GLOBE NEWSWIRE) — Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today…
Pharmaceuticals, Biotechnology and Life Sciences
RADNOR, Pa., Aug. 15, 2024 (GLOBE NEWSWIRE) — Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today…
Approval Helps Solidify NexoBrid’s Position in the U.S. as a Safe and Effective Non-Surgical Burn Treatment for All AgesYAVNE, Israel,…
Inaugural ESG Disclosures Align with the Sustainability Accounting Standards BoardREDWOOD CITY, Calif., Aug. 15, 2024 (GLOBE NEWSWIRE) — Codexis, Inc.…
Approval Expands NexoBrid Target Customer Base to Include Approximately 20 Pediatric Burn Centers CAMBRIDGE, Mass., Aug. 15, 2024 (GLOBE NEWSWIRE)…
The combined company’s shares and warrants are expected to begin trading on Nasdaq under the tickers “SLXN” and “SLXNW”, respectively…
Company demonstrates reliable production from multiple biological sourcesThese manufacturing advancements provide NurExone flexibility in optimizing its exosome production method, ensuring…
WARREN, N.J., Aug. 15, 2024 (GLOBE NEWSWIRE) — In a release issued under the same headline earlier today by Tevogen Bio…
LONDON and NEW YORK, Aug. 15, 2024 (GLOBE NEWSWIRE) — OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing…
ANKARA, Turkey, Aug. 15, 2024 (GLOBE NEWSWIRE) — Protect Pharmaceutical Corp. (OTC: PRTT) (“Company”) announces the appointment of a new…
AUSTIN, Texas, Aug. 15, 2024 (GLOBE NEWSWIRE) — Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for…